Discovery of Niclosamide Analogs with Potent Mitochondrial Uncoupling Activity with reduced toxicity
Jiang, H.; Macorano, A.; Xing, E.; Jedoui, M.; Mohammed, S.; Lee, V.; Cheng, J.; McDonough, L.; Cheng, X.; Ye, J.; Li, P.-K.
Show abstract
Mitochondrial uncouplers have shown clinical potential across various diseases, including cancer. Niclosamide, an FDA-approved anthelmintic drug, acts as a mild mitochondrial uncoupler and has demonstrated anticancer activity in multiple preclinical cancer models. However, its clinical application remains limited, with some attributing this to poor bioavailability, while the underlying mechanisms are still unclear. Here, we demonstrate that niclosamide exhibits a dose-dependent biphasic effect, promoting uncoupling at low concentration while acting as a mitochondrial inhibitor at high concentration, which could restrict its therapeutic window and limit efficacy. To overcome this challenge, we aimed to develop next-generation mitochondrial uncouplers (MUs) by synthesizing and evaluating novel Niclosamide derivatives with enhanced therapeutic potential. Through structural modifications, we optimized uncoupling activity while reducing inhibitory toxicity, thereby expanding the pharmacological window. Our findings suggest that fine-tuning the molecular structure of mitochondrial uncouplers could provide a safer and more effective metabolic reprogramming strategy for cancer treatment.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of DuoMYC: a synthetic cell penetrant miniprotein that efficiently inhibits the oncogenic transcription factor MYC 94%
- Machine learning-augmented molecular dynamics simulations (MD) reveal insights into the disconnect between affinity and activation of ZTPriboswitch ligands 94%
- Discovery and biosynthesis of biffamycin A, a novel glycotetrapeptide antibiotic 93%
Similar papers in this journal
- Development of a new class of liver receptor homolog-1 (LRH-1) agonists by photoredox conjugate addition 94%
- Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3 94%
- Aliphatic Amines are Viable Pro-drug Moieties in Phosphonoamidate Drugs 94%
Similar papers in this journal
- Structure-aided development of small molecule inhibitors of ENPP1, the extracellular phosphodiesterase of the immunotransmitter cGAMP 97%
- An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. 95%
- Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.